Follow The Filings

Avidity Partners Management LP David Witzke

Dallas, TX 21 processed 13Fs on this site, 2021 Q3 to 2026 Q2

  • $624M
  • 45 holdings
  • 2026 Q2
  • +41.2% QoQ
  • Top 5 70.9%

Portfolio

2026 Q2, filed 8/14/2026, top 12 of 45 holdings

Top 5 70.9%, top 10 81.9%

  1. DNTH, Dianthus Therapeutics 32.8%
  2. CGON, CG Oncology 15.9%
  3. ORKA, Oruka Therapeutics 11.6%
  4. JBIO, Jade Biosciences 6.1%
  5. ELVN, Enliven Therapeutics 4.5%
  6. CATX, Perspective Therapeutics 3.4%
  7. AKTS, Aktis Oncology 2.5%
  8. PVLA 1.7%
  9. MOBI, Mobia Medical 1.7%
  10. RGEN, Repligen 1.7%
  11. Immunic 1.6%
  12. Senseonics 1.5%
  13. Other 15.0%

AUM over time

2026 Q2 $624M +41.2% QoQ
2021 Q3: $4.5B 2021 Q3: $4.5B
Q3 2021
2021 Q4: $4.7B, +4.5% QoQ 2021 Q4: $4.7B, +4.5% QoQ
Q4
2022 Q1: $4.8B, +1.9% QoQ 2022 Q1: $4.8B, +1.9% QoQ
Q1 2022
2022 Q2: $4.4B, −9.3% QoQ 2022 Q2: $4.4B, −9.3% QoQ
Q2
2022 Q3: $4.9B, +12.9% QoQ 2022 Q3: $4.9B, +12.9% QoQ
Q3
2022 Q4: $4.6B, −6.2% QoQ 2022 Q4: $4.6B, −6.2% QoQ
Q4
2023 Q1: $3B, −34.7% QoQ 2023 Q1: $3B, −34.7% QoQ
Q1 2023
2023 Q2: $2.9B, −5.0% QoQ 2023 Q2: $2.9B, −5.0% QoQ
Q2
2023 Q3: $2.5B, −13.3% QoQ 2023 Q3: $2.5B, −13.3% QoQ
Q3
2023 Q4: $2.7B, +10.5% QoQ 2023 Q4: $2.7B, +10.5% QoQ
Q4
2024 Q1: $3.1B, +13.0% QoQ 2024 Q1: $3.1B, +13.0% QoQ
Q1 2024
2024 Q2: $2.4B, −24.1% QoQ 2024 Q2: $2.4B, −24.1% QoQ
Q2
2024 Q3: $2B, −16.7% QoQ 2024 Q3: $2B, −16.7% QoQ
Q3
2024 Q4: $1B, −48.1% QoQ 2024 Q4: $1B, −48.1% QoQ
Q4
2025 Q1: $525M, −48.4% QoQ 2025 Q1: $525M, −48.4% QoQ
Q1 2025
2025 Q2: $502M, −4.4% QoQ 2025 Q2: $502M, −4.4% QoQ
Q2
2025 Q3: $439M, −12.5% QoQ 2025 Q3: $439M, −12.5% QoQ
Q3
2025 Q4: $347M, −21.0% QoQ 2025 Q4: $347M, −21.0% QoQ
Q4
2026 Q1: $442M, +27.4% QoQ 2026 Q1: $442M, +27.4% QoQ
Q1 2026
2026 Q2: $624M, +41.2% QoQ 2026 Q2: $624M, +41.2% QoQ
Q2

Book

2022 Q4 2022 Q3, filed 14 Feb, long equity only

Download CSV Download Excel All activity
ARGX, Argenx 5.13%, was 3.53% Add +27.1% 625,000 $378.83 $237M +133,200 +$63M
UTHR, United Therapeutics 4.73% Reduce −19.0% 785,500 $278.09 $218M −184,700 +$15M
NBIX, Neurocrine Biosciences 4.61% Reduce −4.1% 1,780,000 $119.44 $213M −75,700 +$16M
Akero Therapeutics 4.54%, was 2.16% Add +22.5% 3,825,000 $54.80 $210M +703,000 +$103M
PRTA, Prothena 3.85%, was 2.42% Add +50.1% 2,953,000 $60.25 $178M +986,000 +$59M
ARVN, Arvinas 3.67% Add +14.0% 4,950,000 $34.21 $169M +606,500 −$24M
BSX, Boston Scientific 3.26%, was 2.00% Add +28.3% 3,256,700 $46.27 $151M +718,100 +$52M
SNDX, Syndax Pharmaceuticals 3.23%, was 2.73% Add +4.9% 5,861,000 $25.45 $149M +274,100 +$15M
RARE 3.00%, was 1.73% Add +45.7% 2,990,000 $46.33 $139M +938,400 +$54M
Sarepta Therapeutics 2.96%, was 2.13% Add +11.3% 1,055,000 $129.58 $137M +106,800 +$32M
MDGL, Madrigal Pharmaceuticals 2.70% New 430,000 $290.25 $125M +430,000 +$125M
UHS, Universal Health Services 2.52% New 825,600 $140.89 $116M +825,600 +$116M
JAZZ, Jazz Pharmaceuticals 2.51%, was 0.86% Add +128.6% 727,541 $159.31 $116M +409,241 +$73M
ZNTL, Zentalis Pharmaceuticals 2.25%, was 1.86% Add +21.9% 5,150,000 $20.14 $104M +926,900 +$12M
ACHC 2.08%, was 2.21% Reduce −16.1% 1,165,000 $82.32 $96M −224,200 −$13M
SGRY, Surgery Partners 1.88%, was 0.13% Add +1062.9% 3,112,000 $27.86 $87M +2,844,400 +$80M
DXCM, DexCom 1.86%, was 0.77% Add +61.8% 756,800 $113.24 $86M +289,200 +$48M
AZNN 1.76%, was 0.63% Add +113.1% 1,200,000 $67.80 $81M +636,800 +$50M
LLY, Eli Lilly 1.72%, was 6.62% Reduce −78.5% 217,000 $365.84 $79M −790,000 −$246M
PCVX, Vaxcyte 1.68%, was 0.31% Add +156.9% 1,615,400 $47.95 $77M +986,700 +$62M
RNA, Avidity Biosciences 1.57%, was 0.86% Add +26.0% 3,275,000 $22.19 $73M +675,000 +$30M
NTRA, Natera 1.57%, was 1.55% Add +3.7% 1,798,900 $40.17 $72M +63,900 −$3.8M
IDYA, Ideaya Biosciences 1.51%, was 1.13% Add +2.9% 3,824,800 $18.17 $69M +109,400 +$14M
Immunocore 1.43%, was 1.98% Reduce −44.5% 1,154,000 $57.07 $66M −925,100 −$32M
ALT, Altimmune 1.42%, was 0.70% Add +48.7% 3,990,000 $16.45 $66M +1,306,000 +$31M
RVMD, Revolution Medicines 1.28%, was 0.93% Add +6.6% 2,475,000 $23.82 $59M +153,800 +$13M
Karuna Therapeutics 1.27%, was 1.97% Reduce −30.8% 299,000 $196.50 $59M −132,800 −$38M
ARWR, Arrowhead Pharmaceuticals 1.21%, was 0.84% Add +9.5% 1,375,000 $40.56 $56M +119,626 +$14M
AXSM, Axsome Therapeutics 1.12%, was 1.40% Reduce −56.5% 670,000 $77.13 $52M −868,600 −$17M
VRTX, Vertex Pharmaceuticals 1.08%, was 3.02% Reduce −66.5% 172,000 $288.78 $50M −340,800 −$99M
Legend Biotech 1.05% New 970,000 $49.92 $48M +970,000 +$48M
Kezar Life Sciences 1.03%, was 0.95% Add +25.3% 6,782,400 $7.04 $48M +1,368,000 +$1.1M
PLRX, Pliant Therapeutics 0.94%, was 0.84% Add +13.1% 2,240,400 $19.33 $43M +259,300 +$1.9M
Ventyx Biosciences 0.91% New 1,285,000 $32.79 $42M +1,285,000 +$42M
ICLR, Icon 0.90% New 215,000 $194.25 $42M +215,000 +$42M
DGX, Quest Diagnostics 0.87% New 258,000 $156.44 $40M +258,000 +$40M
BIO, Bio Rad Labs 0.84%, was 1.23% Reduce −36.3% 92,200 $420.49 $39M −52,600 −$22M
Bellus Health 0.82% Add +5.8% 4,599,998 $8.22 $38M +253,298 −$8.1M
THC, Tenet Healthcare 0.76% New 717,300 $48.79 $35M +717,300 +$35M
Karyopharm Therapeutics 0.71% New 9,633,911 $3.40 $33M +9,633,911 +$33M
BNTX, Biontech 0.70% New 215,400 $150.22 $32M +215,400 +$32M
Verve Therapeutics 0.66% Add +50.1% 1,565,000 $19.35 $30M +522,294 −$5.5M
RCKT, Rocket Pharmaceuticals 0.65% New 1,527,087 $19.57 $30M +1,527,087 +$30M
Intra-Cellular Therapies 0.58%, was 1.33% Reduce −64.1% 504,000 $52.92 $27M −898,500 −$39M
ARQT, Arcutis Biotherapeutics 0.56%, was 0.31% Add +120.9% 1,755,000 $14.80 $26M +960,500 +$11M
Prometheus Biosciences 0.49% New 204,000 $110.00 $22M +204,000 +$22M
INTC, Intellia Therapeutics 0.48%, was 1.14% Reduce −36.1% 638,200 $34.89 $22M −360,900 −$34M
VIR, Vir Biotechnology 0.47% New 850,000 $25.31 $22M +850,000 +$22M
PHAT, Phathom Pharmaceuticals 0.46% Reduce −0.4% 1,900,000 $11.22 $21M −6,800 +$191K
BHVN, Biohaven 0.45% New 1,492,000 $13.88 $21M +1,492,000 +$21M

Showing top 50 of 82 by value

Exits / last held

Gone since 2022 Q3, shown at their last reported size.

Stock % of portfolio Recent activity Shares Reported price* Value Share change $ change
BIIB, Biogen 3.26% Exit 0 $267.00 $160M −600,000 −$160M
XBI, SPDR Ser Trust 2.39% Exit 0 $79.32 $117M −1,480,000 −$117M
HUM, Humana 2.09% Exit 0 $485.19 $103M −212,000 −$103M
ELV, Elevance Health 1.92% Exit 0 $454.24 $94M −207,600 −$94M
Horizon Therapeutics Pub 1.86% Exit 0 $61.89 $92M −1,482,200 −$92M
AVTR, Avantor 1.80% Exit 0 $19.60 $89M −4,522,600 −$89M
Catalent 1.38% Exit 0 $72.36 $68M −940,000 −$68M
Seagen 1.24% Exit 0 $136.83 $61M −445,500 −$61M
ALNY, Alnylam Pharmaceuticals 1.17% Exit 0 $200.16 $58M −288,500 −$58M
APLS, Apellis Pharmaceuticals 1.17% Exit 0 $68.30 $58M −844,000 −$58M
SYK, Stryker 0.76% Exit 0 $202.54 $37M −184,700 −$37M
CNC, Centene 0.68% Exit 0 $77.81 $34M −432,400 −$34M
NGM Biopharmaceuticals 0.48% Exit 0 $13.08 $24M −1,798,100 −$24M
COGT, Cogent Biosciences 0.41% Exit 0 $14.92 $20M −1,357,700 −$20M
Nkarta 0.38% Exit 0 $13.16 $19M −1,414,082 −$19M
ONC, Beigene 0.36% Exit 0 $134.82 $18M −132,000 −$18M
SIBN, Si-Bone 0.35% Exit 0 $17.46 $17M −996,700 −$17M
Gossamer Bio 0.35% Exit 0 $11.98 $17M −1,450,000 −$17M
ATEC, Alphatec 0.30% Exit 0 $8.74 $15M −1,715,000 −$15M
IOVA, Iovance Biotherapeutics 0.27% Exit 0 $9.58 $13M −1,382,900 −$13M
TMDX, Transmedics Group 0.25% Exit 0 $41.74 $13M −300,000 −$13M
STOK, Stoke Therapeutics 0.23% Exit 0 $12.84 $11M −891,100 −$11M
Seaspine 0.23% Exit 0 $5.68 $11M −2,010,000 −$11M
ERAS, Erasca 0.16% Exit 0 $7.80 $7.7M −982,500 −$7.7M
Bcls Acquisition 0.10% Exit 0 $10.02 $5M −500,000 −$5M
TNGX, Tango Therapeutics 0.06% Exit 0 $3.62 $2.9M −813,700 −$2.9M
Oncosec Medical 0.03% Exit 0 $0.4879 $1.4M −2,945,000 −$1.4M
Sema4 0.02% Exit 0 $0.8779 $834K −950,000 −$834K
Phasebio Pharmaceuticals 0.02% Exit 0 $0.1761 $768K −4,361,365 −$768K
Science 37 0.01% Exit 0 $1.61 $692K −430,000 −$692K

Weight bar: held both quarters added sold at this quarter’s reported price

* Reported price is value ÷ shares from the 13F as of period end, not a live market quote. Weight % is each long-equity position ÷ full 13F AUM, so rows may not sum to 100% when the filing includes options or other non-equity (excluded from this table). Share change and $ change are vs 2022 Q3. Click a column header to sort, or New, Hold, Add or Reduce to bring those moves to the top. Exit opens the last-held block below.

Filings history

20 periods, with AUM normalized

Newest 13Fs
Period Holds AUM QoQ Form Filed Filing ID
2026 Q2 45 $624M +41.2% 13F-HR 8/14/2026 000179182726000005
2026 Q1 45 $494M — new holds 5/28/2026 000179182726000004
2026 Q1 46 $442M +27.4% 13F-HR 5/13/2026 000179182726000003
2025 Q4 39 $347M −21.0% 13F-HR 2/13/2026 000179182726000002
2025 Q3 43 $439M −12.5% 13F-HR 11/14/2025 000179182725000008
2025 Q2 56 $502M −4.4% 13F-HR 8/14/2025 000179182725000007
2025 Q1 67 $525M −48.4% 13F-HR 5/15/2025 000179182725000005
2024 Q4 63 $1B −48.1% 13F-HR 2/14/2025 000179182725000002
2024 Q3 81 $2B −16.7% 13F-HR 11/14/2024 000179182724000011
2024 Q2 85 $2.4B −24.1% 13F-HR 8/14/2024 000179182724000007
2024 Q1 90 $3.1B +13.0% 13F-HR 5/15/2024 000179182724000004
2023 Q4 74 $2.7B +10.5% 13F-HR 2/14/2024 000179182724000002
2023 Q3 83 $2.5B −13.3% 13F-HR 11/14/2023 000179182723000006
2023 Q2 93 $2.9B −5.0% 13F-HR 8/14/2023 000179182723000004
2023 Q1 83 $3B −34.7% 13F-HR 5/15/2023 000179182723000003
2022 Q4 85 $4.6B −6.2% 13F-HR 2/14/2023 000179182723000002
2022 Q3 97 $4.9B +12.9% 13F-HR 11/14/2022 000179182722000008
2022 Q2 82 $4.4B −9.3% 13F-HR 8/15/2022 000179182722000006
2022 Q1 92 $4.8B +1.9% 13F-HR 5/16/2022 000179182722000004
2021 Q4 97 $4.7B +4.5% 13F-HR 2/14/2022 000179182722000002
2021 Q3 105 $4.5B — 13F-HR 11/15/2021 000179182721000006

About

Avidity Partners Management LP

21 processed 13Fs on this site, 2021 Q3 to 2026 Q2

Entity
Avidity Partners Management LP
Notable person
David Witzke
Location
Dallas, TX
All SEC filings
View on sec.gov

Further reading

As an Amazon Associate, FollowTheFilings earns from qualifying purchases.

  • The Essays of Warren Buffett, 8th Ed., Warren Buffett, Lawrence A. Cunningham View on Amazon
  • One Up On Wall Street (Lynch), Peter Lynch View on Amazon

More on the shelf